Qyuns Therapeutics Co., Ltd. (02509) published its monthly return for January 2026, confirming the authorized share capital remains unchanged at 227,071,600 renminbi-denominated ordinary shares, each with a par value of RMB1.

The report shows that the total number of issued shares remained at 227,071,600, comprising 224,874,600 issued shares (excluding treasury shares) and 2,197,000 treasury shares at the end of January. Compared to the previous month, 685,000 shares were repurchased at prices ranging from HKD 19.0769 to HKD 23.1372 on multiple occasions throughout January 2026, thereby increasing the total treasury shares by the same amount.

The company states it has met the Hong Kong Stock Exchange’s public float requirement, which stands at a minimum threshold of 25% for its H shares. The submission was made in compliance with all applicable listing rules and regulatory requirements. No other share options, warrants, convertibles, or similar arrangements were reported for the period.